Fisons and Porton link up

FISONS, the pharmaceutical group, said yesterday that it had linked up with Porton Products, the specialist drug company, to develop and market Fisons' Dopacard product worldwide, writes Gail Counsell.

Dopacard, which already has product licences in the UK, Ireland, the Netherlands, Sweden, Switzerland and New Zealand, is used in connection with heart failure associated with cardiac surgery.

Porton is to seek product licences for Dopacard in countries where they have not yet been agreed, and will work on alternative uses for the drug.

This week Fisons revealed it had formed a strategic alliance with Allergan in the US for the promotion and marketing of its Opticrom eye solution. Fisons has said it wants to have more flexible marketing arrangements for its products.